Skip to main content

Xerion Pharmaceuticals Licenses Xoma Ireland Antibody Expression Technology

NEW YORK, Aug. 13 (GenomeWeb News) --  Xerion Pharmaceuticals of Martinsried, Germany, announced today that it has licensed bacterial expression technology developed by Xoma Ireland.

In a statement, Xerion said it will have rights to use Xoma’s antibody expression technology for developing antibody products derived from phage display libraries for itself and its collaborators. The company also has an option to license the production of antibodies under Xoma patents. Xoma will receive license and royalty payments. The two companies also announced a co-development and commercialization option on antibody products generated by Xerion.

Further financial details were not provided.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.